ALANA CAROLINE COSTA
Projetos de Pesquisa
Unidades Organizacionais
LIM/27 - Laboratório de Neurociências, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Decreased plasmatic spermidine and increased spermine in mild cognitive impairment and Alzheimer's disease patients(2019) JOAQUIM, Helena P. G.; COSTA, Alana C.; FORLENZA, Orestes V.; GATTAZ, Wagner E.; TALIB, Leda L.Background: Current evidence suggests that upregulation of polyamines system plays a role both in cognitive deficit and synaptic loss observed in Alzheimer's disease (AD). Objective: The aim of this study was to determine the plasmatic concentration of polyamines in mild cognitive impairment (MCI) and AD patients in comparison with healthy controls (HC). Methods: Plasmatic polyamines were quantified using the AbsoluteIDQ (R) p1130 and liquid chromatography coupled to tandem mass spectrometry (LC/MS-MS). Results: The study group comprised 34 AD patients, 20 MCI and 25 HC. All individuals were followed for 4 years. During this period 8 amnestic MCI patients (40% of the MCI sample at baseline) converted to AD. Spermidine level was lower in both patient groups (AD; MCI) compared to HC (p = 0.007). Plasma levels of spermine were higher in the MCI group (p < 0.001), but decreased in the sub-sample of MCI patients who converted to AD (p = 0.043). No statistically significant differences were found in ornithine and putrescine levels (p = 0.056 and p = 0.126, respectively). Discussion: Our results suggest dynamic changes in the expression of polyamines in the MCI-AD continuum.
- Plasma metabolites in first episode psychoses(2019) COSTA, Alana C.; JOAQUIM, Helena P. G.; TALIB, Leda L.; SERPA, Mauricio H.; ZANETTI, Marcus V.; GATTAZ, Wagner F.
- Plasma lipids metabolism in mild cognitive impairment and Alzheimer's disease(2019) COSTA, Alana C.; JOAQUIM, Helena P. G.; FORLENZA, Orestes; TALIB, Leda L.; GATTAZ, Wagner F.Objectives: Expression of phospholipids and related molecules could provide panels of multiple biomarkers searching for the signature of Alzheimer's disease (AD). The aim of the present study was to quantify ten phospholipids and simultaneously determine phospholipase A(2) (PLA(2)) activity in blood of mild cognitive impairment (MCI) and AD patients. Methods: Thirty-four AD, 20 MCI and 25 controls were enrolled. The phospholipids where analysed using the AbsoluteIDQp180 Kit. PLA(2) activities were accessed in platelets by a radio-enzymatic assay. Results: The study failed to fix the ten phospholipids as a panel to predict AD; the levels of PCaaC36:6, PCaaC40:6 and C16:1-OH were lower in MCI than in controls (P = 0.041, P = 0.012, P = 0.044 respectively). PCaaC40:2 levels were lower in MCI than in AD (P = 0.041). The converters MCI-AD showed at baseline lower levels of PCaaC40:2 (P = 0.050) and PCaaC40:6 (P = 0.037) than controls. iPLA(2) activity was reduced in AD and MCI than in controls (P < 0.001). We found positive correlation in the control group between PCaaC38:6 and tPLA(2) (r = 0.680; P = 0.001) and sPLA(2) (r = 0.601; P = 0.004); PCaaC40:1 and iPLA(2) (r = 0.503; P = 0.020); PCaaC40:6 and tPLA(2) (r = 0.532; P = 0.013) and sPLA(2) (r = 0.523; P = 0.015). Conclusions: Lipids metabolites in plasma might indirectly indicate changes in neuronal membrane and this deregulation can outline the transition between healthy and diseased brains.